Advanced search
Publication Cover
Cancer Biology & Therapy Volume 14, 2013 - Issue 12
Submit an article Journal homepage
1,458
Views
46
CrossRef citations to date
0
Altmetric
Research Paper

The S492R EGFR ectodomain mutation is never detected in KRAS wild-type colorectal carcinoma before exposure to EGFR monoclonal antibodies

Claudia Esposito Laboratory of Pharmacogenomics; Centro di Ricerche Oncologiche di Mercogliano (CROM); Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione Giovanni Pascale” – IRCCS; Mercogliano (AV), Italy
,
Anna Maria Rachiglio Laboratory of Pharmacogenomics; Centro di Ricerche Oncologiche di Mercogliano (CROM); Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione Giovanni Pascale” – IRCCS; Mercogliano (AV), Italy
,
Maria Libera La Porta Laboratory of Pharmacogenomics; Centro di Ricerche Oncologiche di Mercogliano (CROM); Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione Giovanni Pascale” – IRCCS; Mercogliano (AV), Italy
,
Alessandra Sacco Laboratory of Pharmacogenomics; Centro di Ricerche Oncologiche di Mercogliano (CROM); Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione Giovanni Pascale” – IRCCS; Mercogliano (AV), Italy
,
Cristin Roma Laboratory of Pharmacogenomics; Centro di Ricerche Oncologiche di Mercogliano (CROM); Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione Giovanni Pascale” – IRCCS; Mercogliano (AV), Italy
,
Alessia Iannaccone Laboratory of Pharmacogenomics; Centro di Ricerche Oncologiche di Mercogliano (CROM); Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione Giovanni Pascale” – IRCCS; Mercogliano (AV), Italy
,
Fabiana Tatangelo Surgical Pathology Unit; Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione Giovanni Pascale” – IRCCS; Naples, Italy
,
Laura Forgione Laboratory of Pharmacogenomics; Centro di Ricerche Oncologiche di Mercogliano (CROM); Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione Giovanni Pascale” – IRCCS; Mercogliano (AV), Italy
,
Raffaella Pasquale Laboratory of Pharmacogenomics; Centro di Ricerche Oncologiche di Mercogliano (CROM); Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione Giovanni Pascale” – IRCCS; Mercogliano (AV), Italy
,
Americo Barbaro Laboratory of Pharmacogenomics; Centro di Ricerche Oncologiche di Mercogliano (CROM); Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione Giovanni Pascale” – IRCCS; Mercogliano (AV), Italy
,
Gerardo Botti Surgical Pathology Unit; Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione Giovanni Pascale” – IRCCS; Naples, Italy
,
Fortunato Ciardiello Dipartimento Medico-Chirurgico di Internistica Clinica e Sperimentale “F. Magrassi e A. Lanzara”; Seconda Università degli Studi di Napoli; Napoli, Italy
&
Nicola Normanno Cell Biology and Biotherapy Unit; Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione Giovanni Pascale” – IRCCS; Naples, ItalyCorrespondence[email protected]; [email protected]
 show all
Pages 1143-1146 | Received 19 Jul 2013, Accepted 02 Sep 2013, Published online: 23 Sep 2013

Citations (46)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Timothy Price, Agnes Ang, Michael Boedigheimer, Tae Won Kim, Jin Li, Stefano Cascinu, Paul Ruff, Attili Satya Suresh, Anne Thomas, Sergei Tjulandin & Marc Peeters. (2020) Frequency of S492R mutations in the epidermal growth factor receptor: analysis of plasma DNA from patients with metastatic colorectal cancer treated with panitumumab or cetuximab monotherapy. Cancer Biology & Therapy 21:10, pages 891-898.
Read now
Francesca Battaglin, Vincenzo Dadduzio, Francesca Bergamo, Chiara Manai, Marta Schirripa, Sara Lonardi, Vittorina Zagonel & Fotios Loupakis. (2017) Anti-EGFR monoclonal antibody panitumumab for the treatment of patients with metastatic colorectal cancer: an overview of current practice and future perspectives. Expert Opinion on Biological Therapy 17:10, pages 1297-1308.
Read now
Heng Fong Seow, Wai Kien Yip & Theodora Fifis. (2016) Advances in targeted and immunobased therapies for colorectal cancer in the genomic era. OncoTargets and Therapy 9, pages 1899-1920.
Read now
Nichola Cruickshanks. (2014) When to screen and not to screen. Cancer Biology & Therapy 15:2, pages 147-148.
Read now

Articles from other publishers (42)

Chiara Cremolini, Clara Montagut, Philippe Ronga, Filippo Venturini, Kensei Yamaguchi, Sebastian Stintzing & Alberto Sobrero. (2023) Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer. Frontiers in Oncology 12.
Crossref
Jun Lai & Shuqing Chen. 2023. Antibody-Drug Conjugates and Cellular Metabolic Dynamics. Antibody-Drug Conjugates and Cellular Metabolic Dynamics 13 23 .
Deepak Vangala, Swetlana Ladigan, Sven T. Liffers, Soha Noseir, Abdelouahid Maghnouj, Tina-Maria Götze, Berlinda Verdoodt, Susanne Klein-Scory, Laura Godfrey, Martina K. Zowada, Mario Huerta, Daniel L. Edelstein, Jaime Martinez de Villarreal, Miriam Marqués, Jörg Kumbrink, Andreas Jung, Tobias Schiergens, Jens Werner, Volker Heinemann, Sebastian Stintzing, Doris Lindoerfer, Ulrich Mansmann, Michael Pohl, Christian Teschendorf, Christiane Bernhardt, Heiner Wolters, Josef Stern, Selami Usta, Richard Viebahn, Jacob Admard, Nicolas Casadei, Stefan Fröhling, Claudia R. Ball, Jens T. Siveke, Hanno Glimm, Andrea Tannapfel, Wolff Schmiegel & Stephan A. Hahn. (2021) Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models. Genome Medicine 13:1.
Crossref
Wan-Li Cheng, Po-Hao Feng, Kang-Yun Lee, Kuan-Yuan Chen, Wei-Lun Sun, Nguyen Van Hiep, Ching-Shan Luo & Sheng-Ming Wu. (2021) The Role of EREG/EGFR Pathway in Tumor Progression. International Journal of Molecular Sciences 22:23, pages 12828.
Crossref
Mouade El Bali, Joaira Bakkach & Mohcine Bennani Mechita. (2021) Colorectal Cancer: From Genetic Landscape to Targeted Therapy. Journal of Oncology 2021, pages 1-17.
Crossref
Navgeet Kaur, Anju Goyal & Rakesh K. Sindhu. (2020) Therapeutic Monoclonal Antibodies in Clinical Practice against Cancer. Anti-Cancer Agents in Medicinal Chemistry 20:16, pages 1895-1907.
Crossref
Zi-Nan Li, Lin Zhao, Li-Feng Yu & Min-Jie Wei. (2020) BRAF and KRAS mutations in metastatic colorectal cancer: future perspectives for personalized therapy. Gastroenterology Report 8:3, pages 192-205.
Crossref
E. Martinelli, D. Ciardiello, G. Martini, T. Troiani, C. Cardone, P.P. Vitiello, N. Normanno, A.M. Rachiglio, E. Maiello, T. Latiano, F. De Vita & F. Ciardiello. (2020) Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives. Annals of Oncology 31:1, pages 30-40.
Crossref
Erik J. van Helden, Lindsay Angus, C. Willemien Menke‐van der Houven van Oordt, Daniëlle A. M. Heideman, Eline Boon, Suzanne C. van Es, Sandra A. Radema, Carla M. L. van Herpen, Derk Jan A. de Groot, Elisabeth G. E. de Vries, Maurice P. H. M. Jansen, Stefan Sleijfer & Henk M. W. Verheul. (2019) RAS and BRAF mutations in cell‐free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue‐tested RAS wild‐type advanced colorectal cancer . Molecular Oncology 13:11, pages 2361-2374.
Crossref
Takuro Mizukami, Naoki Izawa, Takako Eguchi Nakajima & Yu Sunakawa. (2019) Targeting EGFR and RAS/RAF Signaling in the Treatment of Metastatic Colorectal Cancer: From Current Treatment Strategies to Future Perspectives. Drugs 79:6, pages 633-645.
Crossref
J. Vidal, B. Bellosillo, C. Santos Vivas, P. García-Alfonso, A. Carrato, M.T. Cano, R. García-Carbonero, E. Élez, F. Losa, B. Massutí, M. Valladares-Ayerbes, J.M. Viéitez, J.L. Manzano, D. Azuara, J. Gallego, S. Pairet, G. Capellá, R. Salazar, J. Tabernero, E. Aranda & C. Montagut. (2019) Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy. Annals of Oncology 30:3, pages 439-446.
Crossref
Qiongna Dong, Bizhi Shi, Min Zhou, Huiping Gao, Xiaoying Luo, Zonghai Li & Hua Jiang. (2019) Growth suppression of colorectal cancer expressing S492R EGFR by monoclonal antibody CH12. Frontiers of Medicine 13:1, pages 83-93.
Crossref
Annika Blank, Daniel Edward RobertsIIII, Heather Dawson, Inti Zlobec & Alessandro Lugli. (2018) Tumor Heterogeneity in Primary Colorectal Cancer and Corresponding Metastases. Does the Apple Fall Far From the Tree?. Frontiers in Medicine 5.
Crossref
Marta Schirripa, Stacey A. Cohen, Francesca Battaglin & Heinz-Josef Lenz. (2018) Biomarker-driven and molecular targeted therapies for colorectal cancers. Seminars in Oncology 45:3, pages 124-132.
Crossref
Livio Trusolino & Simonetta M. Leto. 2018. Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways. Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways 1 27 .
Alain R. Thierry, Brice Pastor, Zhi-Qin Jiang, Anastasia D. Katsiampoura, Christine Parseghian, Jonathan M. Loree, Michael J. Overman, Cynthia Sanchez, Safia El Messaoudi, Marc Ychou & Scott Kopetz. (2017) Circulating DNA Demonstrates Convergent Evolution and Common Resistance Mechanisms during Treatment of Colorectal Cancer. Clinical Cancer Research 23:16, pages 4578-4591.
Crossref
C Nadal, T Winder, A Gerger & David Tougeron. (2017) Future perspectives of circulating tumor DNA in colorectal cancer. Tumor Biology 39:5, pages 101042831770574.
Crossref
Nico Jacobi, Rita Seeboeck, Elisabeth Hofmann & Andreas Eger. (2017) ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology. Cancers 9:12, pages 33.
Crossref
Anna-Lena Geißler, Miriam Geißler, Daniel Kottmann, Lisa Lutz, Christiane D. Fichter, Ralph Fritsch, Britta Weddeling, Frank Makowiec, Martin Werner & Silke Lassmann. (2017) ATM mutations and E-cadherin expression define sensitivity to EGFR-targeted therapy in colorectal cancer. Oncotarget 8:10, pages 17164-17190.
Crossref
Rodrigo Dienstmann, Louis Vermeulen, Justin Guinney, Scott Kopetz, Sabine Tejpar & Josep Tabernero. (2017) Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nature Reviews Cancer 17:2, pages 79-92.
Crossref
Ben Zhao, Lu Wang, Hong Qiu, Mingsheng Zhang, Li Sun, Ping Peng, Qianqian Yu & Xianglin Yuan. (2016) Mechanisms of resistance to anti-EGFR therapy in colorectal cancer. Oncotarget 8:3, pages 3980-4000.
Crossref
Volker Heinemann & Sebastian Stintzing. 2017. Immunotherapy for Gastrointestinal Cancer. Immunotherapy for Gastrointestinal Cancer 217 244 .
Andrea Sartore-Bianchi & Salvatore Siena. 2018. Mechanisms of Drug Resistance in Cancer Therapy. Mechanisms of Drug Resistance in Cancer Therapy 145 159 .
Beth O. Van Emburgh, Sabrina Arena, Giulia Siravegna, Luca Lazzari, Giovanni Crisafulli, Giorgio Corti, Benedetta Mussolin, Federica Baldi, Michela Buscarino, Alice Bartolini, Emanuele Valtorta, Joana Vidal, Beatriz Bellosillo, Giovanni Germano, Filippo Pietrantonio, Agostino Ponzetti, Joan Albanell, Salvatore Siena, Andrea Sartore-Bianchi, Federica Di Nicolantonio, Clara Montagut & Alberto Bardelli. (2016) Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer. Nature Communications 7:1.
Crossref
E. Allen Sickmier, Robert J. M. Kurzeja, Klaus Michelsen, Mukta Vazir, Evelyn Yang & Andrew S. Tasker. (2016) The Panitumumab EGFR Complex Reveals a Binding Mechanism That Overcomes Cetuximab Induced Resistance. PLOS ONE 11:9, pages e0163366.
Crossref
Jiao Yang, Shuting Li, Biyuan Wang, Yinying Wu, Zheling Chen, Meng Lv, Yayun Lin & Jin Yang. (2016) Potential biomarkers for anti-EGFR therapy in metastatic colorectal cancer. Tumor Biology 37:9, pages 11645-11655.
Crossref
F. Ciardiello, N. Normanno, E. Martinelli, T. Troiani, S. Pisconti, C. Cardone, A. Nappi, A.R. Bordonaro, M. Rachiglio, M. Lambiase, T.P. Latiano, G. Modoni, S. Cordio, F. Giuliani, M. Biglietto, V. Montesarchio, C. Barone, G. Tonini, S. Cinieri, A. Febbraro, D. Rizzi, F. De Vita, M. Orditura, G. Colucci, E. Maiello, Vincenzo Iaffaioli, Guglielmo Nasti, Gerardo Botti, F. Tatangelo, Nicoletta Chicchinelli, Mirko Montrone, Annamaria Sebastio, Tiziana Guarino, Gianni Simone, Paolo Graziano, Cinzia Chiarazzo, Gabriele Di Maggio, Laura Longhitano, Mario Manusia, Giacomo Cartenì, Oscar Nappi, Pietro Micheli, Luigi Leo, Sabrina Rossi, Alessandra Cassano, Eugenio Tommaselli, Guido Giordano, Francesco Sponziello, Antonella Marino, Antonio Rinaldi, Sante Romito, Andrea Onetti Muda, Vito Lorusso, Silvana Leo, Sandro Barni, Giuseppe Grimaldi & Michele Aieta. (2016) Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX. Annals of Oncology 27:6, pages 1055-1061.
Crossref
William A. Hammond, Abhisek Swaika & Kabir Mody. (2015) Pharmacologic resistance in colorectal cancer: a review. Therapeutic Advances in Medical Oncology 8:1, pages 57-84.
Crossref
Guoli Chen, Zhaohai Yang, James R. Eshleman, George J. Netto & Ming-Tseh Lin. (2016) Molecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future Perspective. BioMed Research International 2016, pages 1-12.
Crossref
Samra Turajlic & Charles Swanton. (2015) Tracking tumour evolution through liquid biopsy. Nature Reviews Clinical Oncology 12:10, pages 565-566.
Crossref
Giuseppe Bronte, Nicola Silvestris, Marta Castiglia, Antonio Galvano, Francesco Passiglia, Giovanni Sortino, Giuseppe Cicero, Christian Rolfo, Marc Peeters, Viviana Bazan, Daniele Fanale, Antonio Giordano & Antonio Russo. (2015) New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?. Oncotarget 6:28, pages 24780-24796.
Crossref
Teresa Troiani, Stefania Napolitano, Giulia Martini, Erika Martinelli, Claudia Cardone, Nicola Normanno, Donata Vitagliano, Floriana Morgillo, Francesca Fenizia, Matilde Lambiase, Luigi Formisano, Roberto Bianco, Davide Ciardiello & Fortunato Ciardiello. (2015) Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models. Clinical Cancer Research 21:18, pages 4153-4164.
Crossref
Friederike Braig, Manuela März, Aneta Schieferdecker, Alexander Schulte, Mareike Voigt, Alexander Stein, Tobias Grob, Malik Alawi, Daniela Indenbirken, Malte Kriegs, Erik Engel, Udo Vanhoefer, Adam Grundhoff, Sonja Loges, Kristoffer Riecken, Boris Fehse, Carsten Bokemeyer & Mascha Binder. (2015) Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer. Oncotarget 6:14, pages 12035-12047.
Crossref
Elena De Mattia, Erika Cecchin & Giuseppe Toffoli. (2015) Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy. Drug Resistance Updates 20, pages 39-70.
Crossref
M.P. Morelli, M.J. Overman, A. Dasari, S.M.A. Kazmi, T. Mazard, E. Vilar, V.K. Morris, M.S. Lee, D. Herron, C. Eng, J. Morris, B.K. Kee, F. Janku, F.L. Deaton, C. Garrett, D. Maru, F. Diehl, P. Angenendt & S. Kopetz. (2015) Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Annals of Oncology 26:4, pages 731-736.
Crossref
Jamil Akkad, Sylvia Bochum & Uwe M. Martens. (2015) Personalized treatment for colorectal cancer: novel developments and putative therapeutic strategies. Langenbeck's Archives of Surgery 400:2, pages 129-143.
Crossref
Stine Aske Danielsen, Peter Wold Eide, Arild Nesbakken, Tormod Guren, Edward Leithe & Ragnhild A. Lothe. (2015) Portrait of the PI3K/AKT pathway in colorectal cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1855:1, pages 104-121.
Crossref
Sandra Misale, Federica Di Nicolantonio, Andrea Sartore-Bianchi, Salvatore Siena & Alberto Bardelli. (2014) Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent Evolution. Cancer Discovery 4:11, pages 1269-1280.
Crossref
Beth O. Van Emburgh, Andrea Sartore-Bianchi, Federica Di Nicolantonio, Salvatore Siena & Alberto Bardelli. (2014) Acquired resistance to EGFR‐targeted therapies in colorectal cancer. Molecular Oncology 8:6, pages 1084-1094.
Crossref
Simonetta M. Leto & Livio Trusolino. (2014) Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies. Journal of Molecular Medicine 92:7, pages 709-722.
Crossref
Teresa Troiani, Filippo Venturini, Stefania Napolitano, Giulia Martini, Valentina Gambardella, Fortunato Ciardiello & Erika Martinelli. (2014) Predictive biomarkers to anti-EGF receptor inhibitors in the treatment of metastatic colorectal cancer. Colorectal Cancer 3:3, pages 299-308.
Crossref
A. Lièvre. (2014) Des mutations de KRAS aux mutations de RAS : vers une meilleure définition de la réponse aux anticorps anti-EGFR dans le cancer colorectal métastatiqueFrom KRAS mutations to RAS mutations: Towards a better definition of response to anti-EGFR antibodies in metastatic colorectal cancer. Oncologie 16:2-3, pages 120-128.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.